240 results about "Gastric tumor" patented technology

The invention discloses Ilicis routundae cortex derivants and an application thereof in preparing a medicament capable of resisting tumors. Ilicis routundae cortex acid is obtained by extracting, separating and purifying traditional Chinese medicine Ilicis routundae cortex to serve as a lead compound; the lead compound is subjected to corresponding chemical reaction to prepare a series of derivants. The pharmacological test proves that the Ilicis routundae cortex derivants have the function of resisting tumor activity and have inhibition action on prostatic cancer cells, lung cancer cells, liver cancer cells, cervical cancer cells and gastric cancer cells; and the inhibiting effects on the tumor cells by the derivants are superior to that of parent nucleus Ilicis routundae cortex.

Objective methods for detecting and diagnosing intestinal-type gastric cancers are described herein. Also described is method for predicting the presence or absence of lymph node metastasis (i.e., identifying the metastatic phenotype). In one embodiment, the diagnostic method involves the scoring of gene expression profiles that discriminate between lymph node positive tumors and lymph node negative tumors. The predictive score calculated acts as diagnostic indicator that can objectively indicate whether a sample tissue has the metastatic phenotype. The present invention further provides methods of diagnosing intestinal-type gastric cancer in a subject, methods of screening for therapeutic agents useful in the treatment of intestinal-type gastric cancer, methods of treating intestinal-type gastric cancer and method of vaccinating a subject against intestinal-type gastric cancer.

The invention discloses a preparation method of an electrochemical mark-free immunosensor of a gastric cancer tumor marker, and belongs to the field of a novel nano functional material and a biosensor. Firstly, a titanium dioxide-noble metal composite material is directly synthesized on an electrode on a titanium dioxide nano particle substrate by using a photoelectrical chemical synthesis method; furthermore, the electrochemical mark-free immunosensor of the gastric cancer tumor marker, which has the advantages of low cost, high sensitivity, good specificity, rapidness in detection and simplicity in operation, is prepared.

The invention belongs to the technical field of chip detection and particularly discloses an antibody chip kit for detecting early gastric cancer. The antibody chip kit is characterized in that various gastric cancer marker related antibodies are fixed onto a solid-phase carrier, and the specific antibodies are screened from 35 routine gastric cancer marker related antibodies. The antibody chip kit can detect a plurality of gastric cancer related antigen proteins at the same time, and the detection effect of a combined antibody chip is better than that of single tumor markers.

The invention discloses gene sets and a scoring model for evaluating a tumor microenvironment, and application of the gene sets, and belongs to the field of biological information. It is proved for the first time that the gastric cancer has remarkable tumor microenvironment typing, and prognosis difference of gastric cancer patients with different typing is remarkable. According to a constructionmethod of the multi-gene scoring model for evaluating the gastric cancer tumor microenvironment, 44 gene sets capable of representing different microenvironment types are screened out, and the prediction efficiency of the tumor microenvironment multi-gene scoring model corresponding to the gene sets is remarkably better than that of other existing models; and the model is not only a prognostic marker of a gastric cancer patient, but also has a quite remarkable prediction effect in pan-cancer. The model provided by the invention not only can be used as a good prognosis biomarker, but also can be used for predicting checkpoint inhibitor immunotherapy response of various tumors by effectively evaluating the tumor microenvironment, and has important significance and clinical application valuefor better screening immunotherapy benefiting people.

The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.

The invention relates to an application of a black raspberry extract (BRBE) in preparation of drugs for treating gastric cancer. According to the invention, the BRBE can be mixed with a pharmaceutical excipient to prepare a clinically acceptable anti-tumor preparation used for treating gastric cancer, and the total effective dose of the BRBE is 0.5-1g/kg/d. Found by anti-cancer experiment researches of in vitro various human gastric tumor cells and in vivo tumor animal models, the BERE has a better inhibitory action on the in vitro tumor cells and a quite obvious effect on preventing and treating the gastric cancer.

The invention discloses a dominant sequence GTM of a delta 1 chain complementary determining region (CDR) 3 in human gastric cancer tissue-derived tumor-infiltrating gamma delta T lymphocytes, a T cell receptor (TCR) containing the sequence, and TCR transfected cells. The amino acid residue sequence of the GTM is shown as SEQ ID NO.1 in a sequence table. Experiments prove that GTM peptide can be specifically combined with tumor cells, tumor tissue and V delta 1 T cell ligand MICA protein; and a J.RT3-T3.5 cell platform for expressing the TCR containing the dominant sequence GTM of the delta 1 chain CDR3 in the human gastric cancer tissue-derived tumor-infiltrating gamma delta T lymphocytes on a J.RT3-T3.5 surface is established by a lentivirus expression system, gamma delta 1 tumor-infiltrating lymphocytes (TIL) and a tumor identifying and killing mechanism thereof are simulated in the cell level, the killing activity of the transfected cells TCR gamma 4 delta 1 on the tumor cells is obviously increased, and the killing effect is TCR-dependent. The invention plays an important role in the development of medicines for treating malignant tumors and the adoptive treatment of malignant tumors, and has wide application prospects.

The invention discloses a targeted protein degradation c-Met degradation agent as well as a preparation method and application thereof. The invention provides a c-Met degradation agent based on a targeted protein degradation PROTAC strategy, a preparation method thereof and application of the c-Met degradation agent in the treatment of non-small cell lung cancer, gastric cancer and other cancers.The compound has a remarkable c-Met degradation effect and a remarkable cell proliferation inhibition effect, has the potential of serving as an anti-tumor drug to treat tumors, shows remarkable proliferation inhibition activity in an EBC1 drug-resistant cell strain constructed by lentiviral transfection, is obviously superior to a small molecule inhibitor LXM262. and obviously improves the cell selectivity. The compound has significant advantages in overcoming tumor c-Met acquired drug resistance, especially the compound S27 only provides good activity for c-Met dependent EBC-1 lung cancer cells, it is indicated that the compound S27 has good cell selectivity while the original small molecule inhibitor is multi-target, and the compound also has an inhibition effect on a c-Met non-dependent cell line.

The invention belongs to the biological medicine field, in particular relating to the use of a high efficiency small interfering RNA for preparing a tumor migration inhibition drug. The high efficiency small interfering RNA can silence the expression of survivin, change the adhesive force of breast cancer, gastric cancer and liver cancer cells against IV collagen, and inhibit the migrating ability of the breast cancer, gastric cancer and liver cancer cells at two-and three-dimensional levels. The small interfering RNA can also prepare the drug for inhibiting the tumor migration.

The invention provides a pyrazolo-[1,5-a] pyrimidine derivative. The invention further provides activity screening results of the cell level and the target level of the compound and an anti-tumor application of the compound for treating diseases or symptoms, such as gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer. The invention further provides a relevant experiment for the cell level of the compound. The cell level comprises an inhibitory test on a TRPC6 channel and growth inhibitory activity on gastric cancer cells.

The invention discloses traditional Chinese medicine for treating esophagus cancer, gastric cancer, liver cancer and brain tumor. The traditional Chinese medicine is characterized by being prepared from the following Chinese medicinal materials in parts by weight: 35-150 parts of common monkshood root, 8-35 parts of tatarian aster root, 8-35 parts of Chinese thorowax root, 8-35 parts of grassleaf sweelflag rhizome, 8-35 parts of officinal magnolia bark, 8-35 parts of platycodon root, 8-35 parts of Chinese honey locust fruit, 8-35 parts of medicinal evodia fruit, 8-35 parts of dried ginger, 8-35 parts of coptis root, 8-35 parts of ginseng, 8-35 parts of white poria, 8-35 parts of cassia bark, 8-35 parts of croton seed and 8-35 parts of fructus zanthoxyli. The invention further discloses a preparation method of the traditional Chinese medicine. The method comprises the following steps: preparing weighted Chinese medicinal materials into mixed Chinese medicinal powder; mixing the mixed Chinese medicinal powder with honey to obtain pills. The Chinese medicinal composition has the characteristics of small side effects and prevention of relapse after healing.

The invention discloses a method for constructing a tumor xenograft model in mice immunized with gastric cancer based on an organ-like method, and an application thereof. The invention relates to a medical tumor animal model, based on an organ-like method. For the first time, the present invention employs a quasi-organ technique, that is, using a microcarrier as substrate. The composite human gastric cancer cell line SGC-7901/MKN-45 is transplanted subcutaneously into C57BL/6 mice to establish a tumor model of human gastric cancer with normal immune function. The tumor model constructed by this method has good tumorigenicity, and the tumorigenicity rate is up to 75%. The HE staining and the immunohistochemistry of the transplanted tumor accord with the characteristics of human gastric cancer. Compared with the existing immunodeficient mice transplanted tumor model, the model can better study and further clarify the mechanism of tumor occurrence and development in the normal immune system, and also provides a more valuable new animal model for the research and development of anticancer drugs. The invention is applied to the tumor model field.

The invention discloses a medicament for treating epithelium tumor which comprises the following constituents (by weight percentage): curcumin 0.1-90%, catechin 0.1-90%, quercetin 0.1-90%, OPC 0.1-90%, ginseng saponin 0.1-90% and polysaccharides 0.1-90%.

The invention relates to the field of genetic engineering, in particular to a novel fungal immunomodulatory protein FIP-NHA with antineoplastic activity and a gene thereof. The fungal immunomodulatory protein FIP-NHA according to the invention has an amino acid sequence as shown in SEQ ID NO. 1, and the gene fip-nha for coding the fungal immunomodulatory protein has a nucleotide sequence as shownin SEQ ID NO. 2. The fungal immunomodulatory protein FIP-NHA provided by the invention has the effects on promoting splenic lymphocyte division, increasing synthesis of interleukin 2, and obviously inhibiting proliferation of three tumor cells including hepatoma cell HepG2, gastric cancer cell MGC823 and leukemia cell HL60, therefore, the fungal immunomodulatory protein FIP-NHA as a novel antineoplastic biological agent can be widely used in the fields of health products and biological medicines.

The invention discloses a new mono-tetrahydrofuran type sugar apple lactone compound with anti-tumor activity, through systematic in-depth research of chemical ingredients of sugar apple seeds, the analysis of wave spectrum and mass spectrum data shows that the new mono-tetrahydrofuran type sugar apple lactone compound (Anno Shikemominbing) can be separated from the sugar apple seeds, in vivo and in vitro anti-tumor activity researches show that mono-tetrahydrofuran type sugar apple lactone provided by the invention has very strong anti-tumor activity for a variety of tumor cells, including lung cancer, breast cancer, liver cancer, cervical cancer and gastric cancer, and the toxicity test research shows that the mono-tetrahydrofuran type sugar apple lactone compound with the anti-tumor activity provided by the invention is expected to be developed into new anti-tumor medicaments.

Gastrointestinal track (GIT) including oesophageal and gastric cancers are a leading cause of cancer death worldwide. Limited therapeutic options highlight the need to understand the molecular changes responsible for the disease and to develop therapies based on this understanding. Advances in understanding the molecular changes responsible for GIT cancer etiology and progression are expected to improve disease diagnosis and treatment. The glutathione peroxidase 7 (GPX7) a candidate tumor suppressor implicated in GIT cancers including esophageal and gastric cancers has been implicated as a potential tumor suppressor gene in esophageal and gastric cancers; however, this claim is controversial. The goal of this invention is to develop cell-permeable (CP-) form of GPX7 to utilize the therapeutic potential of GPX7 in the treatment of GIT cancers. Using macromolecule intracellular transduction technology (MITT) enabled by novel hydrophobic cell-penetrating peptide (CPP) called advanced macromolecule transduction domains (aMTDs) which are able to promote protein uptake by mammalian cells and tissues, the first CP-GPX7 protein has been developed to deliver biologically active GPX7 protein into human oesophageal and gastric cancer cells, resulting in suppression of cell phenotypes and induction of changes in biomarker expression consistent with previously described effects of GPX7. CP-GPX7 recombinant protein fused to aMTD also suppresses the growth of human gastric tumors in a mouse xenograft model. The results of this art provide further evidence that GPX7 can function as an anti-cancer molecule and suggest that practical methods to augment GPX7 function could be useful in treating of some types of GIT cancers. The present art with CP-GPX7 recombinant protein illustrates the use of protein-based therapies to target GIT cancers.

There is provided a grouping for classifying a gastric cancer tumor sample obtained from a patient suffering or suspected to suffer from gastric cancer, wherein the grouping comprises an invasive subtype, a proliferative subtype and a metabolic subtype. There is also provided a predictor and methods of using the grouping.

The present invention relates to a humanized antibody binding to claudin 18.2 for treating cancer. The antibody does not bind to Claudin 18.1, but selectively binds to Claudin 18.2 to destroy tight connection between cells, so that the Claudin 18.2 cannot exert normal functions, and the antibody can be used for preventing or treating tumors, especially advanced gastric cancer.